kabutan

Astellas Pharma Inc.(4503) Summary

4503
TSE Prime
Astellas Pharma Inc.
2,244.0
JPY
-58.0
(-2.52%)
Jan 16, 3:30 pm JST
14.16
USD
Jan 16, 1:30 am EST
Result
PTS
outside of trading hours
2,250
Jan 17, 1:05 am JST
Summary Chart Historical News Financial Result
PER
22.3
PBR
2.49
Yield
3.48%
Margin Trading Ratio
30.74
Stock Price
Jan 16, 2026
Opening Jan 16, 9:00 am
2,299.0 JPY 14.49 USD
Previous Close Jan 15
2,302.0 JPY 14.51 USD
High Jan 16, 9:00 am
2,299.5 JPY 14.49 USD
Low Jan 16, 12:30 pm
2,232.5 JPY 14.08 USD
Volume
8,426,800
Trading Value
0.02T JPY 0.12B USD
VWAP
2251.58 JPY 14.22 USD
Minimum Trading Value
224,400 JPY 1,416 USD
Market Cap
4.06T JPY 0.03T USD
Number of Trades
10,147
Liquidity & Number of Trades
As of Jan 16, 2026
Liquidity
High
1-Year Average
6,290
1-Year High Feb 12, 2025
24,753
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jan 9, 2026 674,600 904,200 1.34
Dec 26, 2025 657,100 1,140,300 1.74
Dec 19, 2025 677,500 1,182,500 1.75
Dec 12, 2025 719,100 1,192,300 1.66
Dec 5, 2025 687,400 1,208,300 1.76
Company Profile
Astellas Pharma Inc. is the second-largest pharmaceutical company in Japan, specializing in innovative drugs. The company has particular strengths in urology and transplantation, and is focusing on anticancer drugs.
Sector
Pharmaceuticals
Astellas Pharma Inc. was formed in 2005 through the merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical. The company's main business is the research and development, manufacturing, and sales of pharmaceuticals, with operations spanning globally. In research and development, Astellas focuses on cutting-edge fields such as regenerative medicine and gene therapy, primarily through its U.S. subsidiaries. The company has 11 production sites worldwide, including in Ireland, the Netherlands, and China. Its sales network covers approximately 70 countries where it conducts direct sales, including the United States, Germany, China, France, Spain, and South Korea. Astellas has established an integrated pharmaceutical business across its group, collaborating with regional affiliates to supply raw materials and products. The company operates in a single business segment - pharmaceuticals - leveraging its global R&D infrastructure and sales network for business expansion.